Pipeline
Develop antibody drugs to meet patients' needs
Biocytogen is committed to developing innovative antibody drugs that meet the needs of patients, focusing on oncology, autoimmune, inflammatory, metabolic and and other diseases. Taking full advantage of its unique advantage in innovative drug development the company now has more than 10 R & D pipelines including monoclonal antibodies, bispecific antibodies, ADC drugs and so on. With the support of a strong clinical development team and abundant clinical resources, the company will push forward the product pipeline at full speed to accelerate the clinical trial process.
Therapeutic Area
Products
Target
Partner
Molecular Format
Indication
Status
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Oncology
BCG008
SIGLEC15
UNDISCLOSED
Monoclonal Antibody
Solid Tumors
Infectious Diseases
Oncology
YH003
More
Target：
CD40
Partner：
Molecular Format：
Monoclonal antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH001
More
Target：
CTLA-4
Partner：
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH002
More
Target：
OX40
Partner：
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH004
More
Target：
4-1BB
Partner：
Molecular Format：
Monoclonal antibody
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH005
More
Target：
Claudin18.2- ADC
Partner：
Remegen
Molecular Format：
ADC
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH008
More
Target：
PD-1 x CD40
Partner：
Molecular Format：
Bispecific antibody
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH006
More
Target：
CTLA-4 x OX40
Partner：
Molecular Format：
Bispecific antibody
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH010
More
Target：
PD-L1 x IL12
Partner：
Molecular Format：
Bispecific antibody
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH011
More
Target：
PD-L1 x cytokine
Partner：
GeneQuantum
Molecular Format：
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH012
More
Target：
HER2 x TROP2
Partner：
Molecular Format：
Bispecific ADC
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
YH013
More
Target：
EGFR x MET
Partner：
Molecular Format：
Bispecific ADC
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG003
More
Target：
TNFR2
Partner：
Dragonboatbio
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG001
More
Target：
B7-H3
Partner：
Mabworks
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG008
More
Target：
SIGLEC15
Partner：
UNDISCLOSED
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG002
More
Target：
CD24
Partner：
UNDISCLOSED
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG005
More
Target：
CCR8
Partner：
LiberoThera
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
BCG007
More
Target：
AMHR2
Partner：
UNDISCLOSED
Molecular Format：
Monoclonal Antibody
Indication：
Solid Tumors
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Infectious Diseases
YH009
More
Target：
RSV
Partner：
Molecular Format：
Monoclonal antibody
Indication：
Discovery
Pre-clinical
IND
Phase l
Phase ll
Phase lll
BLA
Biocytogen has reached licensing agreements on its proprietary human antibody mice based discovery platforms and strategic antibody drug co-development partnerships with many pharmaceutical companies around the world. Click the button below to learn more about the collaboration models.For pipeline related collaboration, please contact: BD-Licensing@biocytogen.com
Partnering
+86-010-56967680
Copyright © 2022 Biocytogen. All Rights Reserved
Powered by Fractal-technology